Open access · US-GOV via ClinicalTrials.gov Clinical trial

Tau PET Imaging in the NACC Study Cohort: Modulators of MTL Subregion Structure and Function in Normal and Pathological Aging

Authors not listed

University of Pennsylvania · 2017

Chronic inflammation Human Randomized controlled trial

Abstract

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). 18F-AV-1451 is a specialized radioactive PET imaging agent that is able to detect the presence of tau in the brain. In this study, the investigator will use the 18F-AV-1451 to capture images of tau in the brain. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of very early Alzheimer's disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-29 MST

Cite this

APA

Anonymous. (2017). Tau PET Imaging in the NACC Study Cohort: Modulators of MTL Subregion Structure and Function in Normal and Pathological Aging. <em>University of Pennsylvania</em>. https://clinicaltrials.gov/study/NCT03189485

Vancouver

Anonymous. Tau PET Imaging in the NACC Study Cohort: Modulators of MTL Subregion Structure and Function in Normal and Pathological Aging. University of Pennsylvania. 2017.

BibTeX

@misc{anon2017TauPET, title = {Tau PET Imaging in the NACC Study Cohort: Modulators of MTL Subregion Structure and Function in Normal and Pathological Aging}, author = {Anonymous}, journal = {University of Pennsylvania}, year = {2017}, }